Goldman Sachs
RUBY

Goldman Sachs’s Rubius Therapeutics, Inc RUBY Stock Holding History

Goldman Sachs’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,511
Closed -$3.06K – 6426
2022
Q4 		$3.06K Sell
17,511
-27,010
-61% -$7.38K ﹤0.01% 5845
2022
Q3 		$19K Sell
44,521
-234,387
-84% -$176K ﹤0.01% 5952
2022
Q2 		$238K Sell
278,908
-105,845
-28% -$178K ﹤0.01% 5560
2022
Q1 		$2.12M Sell
384,753
-18,088
-4% -$115K ﹤0.01% 4210
2021
Q4 		$3.9M Buy
402,841
+30,222
+8% +$419K ﹤0.01% 3657
2021
Q3 		$6.66M Buy
372,619
+206,659
+125% +$4.5M ﹤0.01% 3106
2021
Q2 		$4.05M Buy
165,960
+69,809
+73% +$1.75M ﹤0.01% 3539
2021
Q1 		$2.55M Sell
96,151
-9,354
-9% -$137K ﹤0.01% 3748
2020
Q4 		$801K Sell
105,505
-39,090
-27% -$232K ﹤0.01% 4340
2020
Q3 		$724K Buy
144,595
+24,598
+20% +$130K ﹤0.01% 4286
2020
Q2 		$718K Buy
119,997
+21,220
+21% +$125K ﹤0.01% 4168
2020
Q1 		$440K Buy
98,777
+7,167
+8% +$53.2K ﹤0.01% 4288
2019
Q4 		$871K Buy
91,610
+24,589
+37% +$238K ﹤0.01% 4210
2019
Q3 		$526K Buy
67,021
+4,486
+7% +$52.3K ﹤0.01% 4424
2019
Q2 		$984K Buy
62,535
+11,330
+22% +$183K ﹤0.01% 4007
2019
Q1 		$927K Buy
51,205
+15,395
+43% +$236K ﹤0.01% 4099
2018
Q4 		$576K Buy
+35,810
New +$653K ﹤0.01% 4281

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Goldman Sachs's RUBY Position: Q1 2023 in Review

Goldman Sachs sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 17,511 shares — an estimated $3.06K sold.

Goldman Sachs first reported a position in RUBY in Q4 2018 and held it in 17 quarters. The position peaked at $6.66M in Q3 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Goldman Sachs reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Goldman Sachs sold 17,511 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $3.06K.
  • Goldman Sachs first reported a position in Rubius Therapeutics, Inc in Q4 2018 and held it in 17 quarters.
  • Goldman Sachs's Rubius Therapeutics, Inc position peaked at $6.66M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.